{"filings":[{"id":1535799,"accession_number":"0001193125-26-299165","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2026-07-09T12:00:16+00:00","items":["5.02"],"status":"ready","headline":"Vera Therapeutics announces CRO transition: Turner to Special Advisor, Bowman appointed Chief Regulatory Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Turner steps down as Chief Regulatory Officer, becomes Special Advisor for Regulatory Affairs effective August 3, 2026.","Nancy Bowman, M.D., Ph.D., appointed as new Chief Regulatory Officer, effective August 3, 2026.","Transition appears planned; no reason for departure given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1490756,"accession_number":"0001193125-26-297211","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2026-07-07T16:45:57+00:00","items":["8.01"],"status":"ready","headline":"FDA grants accelerated approval for Vera's TRUTAKNA (atacicept) in IgA nephropathy","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.","Approval announced on July 7, 2026; this is a significant regulatory milestone for Vera Therapeutics.","The accelerated approval is based on reduction of proteinuria as a surrogate endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-07","daily_digest_url":"/daily/2026-07-07","daily_digest_rank":5},{"id":787477,"accession_number":"0001193125-26-252475","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2026-06-02T11:05:16+00:00","items":["8.01"],"status":"ready","headline":"Vera Therapeutics announces FDA alignment on earlier eGFR analysis for atacicept; results expected Q3 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed to revised ORIGIN 3 eGFR analysis plan to support potential full approval of atacicept in IgA Nephropathy.","eGFR results now expected in the third quarter of 2026.","Company plans to submit supplemental Biologics License Application for full approval in Q4 2026.","Alignment could accelerate path to full approval for atacicept."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":669516,"accession_number":"0001193125-26-239559","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2026-05-26T20:54:31+00:00","items":["5.07"],"status":"ready","headline":"Vera Therapeutics stockholders elect three Class II directors, ratify KPMG, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Michael M. Morrisey elected with 45.3M For, 13.8M Withheld; Patrick G. Enright with 54.7M For; James R. Meyers with 58.9M For.","Ratification of KPMG as auditor for FY 2026 approved (61.8M For, 44.7K Against, 87.3K Abstain).","Advisory vote on executive compensation approved (56.6M For, 2.4M Against, 84.3K Abstain, 2.9M Broker non-votes).","71.7M shares outstanding and entitled to vote as of record date March 24, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95979,"accession_number":"0001193125-26-210351","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q1 net loss widens to $1.69/shr; atacicept gets priority review with PDUFA July 7","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $121.0M in Q1 2026 vs $51.7M in Q1 2025; diluted EPS loss of $1.69 vs $0.81.","Cash, equivalents and marketable securities at $596.8M; expects to fund operations beyond expected launch.","FDA accepted atacicept BLA for priority review with PDUFA date of July 7, 2026 for IgAN.","Matt Skelton promoted to CCO; Jane Wright-Mitchell appointed Chief Legal Officer; Christopher Hite added to board.","Initial Phase 2 PIONEER basket trial results expected Q2 2026; pivotal eGFR data from ORIGIN 3 expected Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109454,"accession_number":"0001193125-26-098783","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vera Therapeutics appoints Christopher Hite to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Hite appointed as Class III Director effective March 5, 2026.","Initial option grant for 24,937 shares at $38.85, vesting monthly over three years.","Annual cash retainer of $45,000, pro-rated for 2026.","Eligible for annual option grants from 2027: lesser of 18,000 shares or up to $400k in grant date fair value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109453,"accession_number":"0001193125-26-073421","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics reports FY 2025 net loss $299.6M; FDA priority review for atacicept PDUFA July 7, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $299.6M (diluted EPS -$4.66), vs $152.1M loss in FY 2024.","Cash, equivalents, and marketable securities $714.6M as of Dec 31, 2025, expected to fund through atacicept launch.","FDA granted priority review for atacicept BLA in IgA nephropathy; PDUFA date July 7, 2026.","Completed $800M equity/debt financings; potential U.S. commercial launch mid-2026 if approved.","Appointed James R. Meyers to Board; Phase 2 PIONEER basket trial results expected 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125957,"accession_number":"0001193125-25-323298","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vera Therapeutics Announces Departure of Chief Legal Officer Jason Carter","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Carter will cease to be Chief Legal Officer of Vera Therapeutics, effective December 24, 2025.","The departure was announced on December 16, 2025, and filed on Form 8-K.","No reason for the departure was disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125956,"accession_number":"0001193125-25-314430","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vera Therapeutics prices public offering of 6.14M shares at $42.50, raising ~$260.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered underwriting agreement Dec 9 to sell 6,138,108 shares of common stock at $42.50/share.","Gross proceeds to company approximately $260.9 million before underwriting discounts and expenses.","Underwriters fully exercised 30-day over-allotment option for 920,716 additional shares on Dec 10.","Offering expected to close Dec 11, 2025, subject to customary conditions.","Shares offered under existing automatic shelf registration statement (File No. 333-282861)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125955,"accession_number":"0001193125-25-300647","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vera Therapeutics appoints James R. Meyers to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James R. Meyers appointed as Class II Director effective Nov 25, 2025; term expires at 2026 annual meeting.","Appointed to Audit Committee; received nonstatutory stock option for 25,000 shares vesting monthly over 3 years.","Annual cash retainer of $40k plus $10k Audit Committee retainer, pro-rated for 2025.","Eligible for annual option grant at 2026 meeting: lesser of 14,000 shares or fair value not exceeding $400,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125954,"accession_number":"0001193125-25-268331","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vera Therapeutics announces atacicept Phase 3 data: 46% proteinuria reduction, 42% vs placebo (p<0.0001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Atacicept achieved 46% reduction from baseline in UPCR at week 36; 42% reduction vs placebo (p<0.0001).","Secondary endpoints: Gd-IgA1 reduced by 68%; hematuria resolved in 81% of participants with baseline hematuria.","Safety profile favorable: serious adverse events 0.5% (atacicept) vs 5% (placebo); no deaths in either group.","eGFR results not disclosed per FDA recommendation to sponsors of IgAN registrational trials.","Data presented at ASN Kidney Week and simultaneously published in The New England Journal of Medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125953,"accession_number":"0001193125-25-265799","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q3 net loss $80.3M; atacicept BLA submission on track for Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $80.3M ($1.26/sh) vs $46.6M ($0.85) in Q3 2024; cash & securities $497.4M.","BLA for atacicept in IgA nephropathy under Accelerated Approval submitted to FDA expected Q4 2025.","ORIGIN 3 36-week results presented as late-breaking oral at ASN Kidney Week on Nov 6, 2025.","PIONEER basket trial and ORIGIN Extend study actively enrolling; initial PIONEER data expected Q4 2025.","Potential FDA approval and U.S. commercial launch of atacicept anticipated in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142691,"accession_number":"0001193125-25-173591","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Vera Therapeutics enters $200M at-the-market equity offering agreement with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Sales Agreement with TD Cowen to sell up to $200M of Class A common stock from time to time.","Prior $200M ATM agreement with TD Cowen terminated effective August 5, 2025.","TD Cowen will receive up to 3.0% commission on gross proceeds of shares sold.","Company not obligated to sell any shares; sales subject to company instructions and market conditions.","Issuance will be made under existing S-3 shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142690,"accession_number":"0000950170-25-102399","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q2 net loss $76.5M; on track to submit atacicept BLA in Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $76.5M ($1.20 per share) vs $33.7M ($0.62) year-over-year; cash $556.8M as of June 30, 2025.","Positive ORIGIN 3 trial: 46% proteinuria reduction with atacicept; 42% vs placebo (p<0.0001).","BLA submission for accelerated approval of atacicept in IgAN expected Q4 2025; commercial launch targeted 2026.","Secured up to $500M credit facility with Oxford Finance, extending cash runway past potential launch.","Initiated PIONEER basket trial for atacicept in expanded IgAN, pMN, FSGS, and MCD populations."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160763,"accession_number":"0001193125-25-133730","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Vera Therapeutics enters up to $500M loan facility with Oxford Finance; $75M initial draw","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $75M funded June 4, 2025; remaining $50M from $125M first tranche drawable in 2026.","Additional tranches: up to $175M upon milestones, plus $200M uncommitted subject to mutual agreement.","Interest rate: greater of 1-Month Term SOFR + 4.95% and 8.70%; maturity June 2030 or 2031.","Collateral on substantially all assets except IP; financial covenants require minimum liquidity or loan coverage ratios.","Facility fee 0.75% of funded amount; final payment and prepayment fees apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160762,"accession_number":"0001193125-25-132736","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vera Therapeutics atacicept Phase 3 IgAN trial meets primary endpoint; 46% proteinuria reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Atacicept achieved 46% reduction from baseline in UPCR, 42% vs placebo (p<0.0001) at week 36.","Safety profile favorable and comparable to placebo in the ORIGIN Phase 3 trial of 431 adults.","Vera plans to submit BLA for accelerated approval to FDA in Q4 2025; commercial launch targeted for 2026.","Trial continues blinded to assess eGFR over two years, expected completion in 2027.","No eGFR results shared at this time per FDA guidance; full results to be presented at ASN Kidney Week."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160761,"accession_number":"0000950170-25-074446","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders re-elect three Class I directors, ratify KPMG, and approve executive compensation on advisory basis","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected three Class I directors (Fordyce, Seidenberg, Hall) each with >49M votes for, ~5.4M withheld, and 1.8M broker non-votes.","Ratified KPMG LLP as auditor for FY2025 with 56.6M votes for and only 3,556 against.","Advisory 'Say-on-Pay' approved with 52.98M votes for (96.6% of votes cast).","Stockholders recommended annual advisory vote on executive compensation (54.8M votes for 'One Year'); company to hold annual votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160760,"accession_number":"0000950170-25-063975","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q1 net loss $51.7M; on track for Phase 3 atacicept results in 2Q 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $51.7M ($0.81/share) vs $28.4M ($0.56/share) same quarter last year.","Cash, equivalents and marketable securities of $589.8M as of March 31, 2025.","Primary endpoint results from atacicept pivotal Phase 3 ORIGIN trial in IgAN expected in 2Q 2025.","BLA submission for atacicept accelerated approval planned for 4Q 2025; potential launch in 2026.","Expanded atacicept program into primary membranous nephropathy, FSGS, and minimal change disease."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178958,"accession_number":"0000950170-25-027337","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics reports 2024 net loss $152.1M; atacicept Phase 3 primary endpoint due Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $152.1M ($2.75 diluted EPS) vs $96.0M ($2.25) in 2023; cash burn $134.7M operating.","Cash and equivalents $640.9M as of Dec 31, 2024; sufficient through potential 2026 commercial launch.","Phase 3 ORIGIN trial primary endpoint expected Q2 2025; BLA submission for atacicept planned H2 2025.","Expanded pipeline: atacicept in PMN, FSGS, MCD; acquired next-gen fusion protein VT-109 in 2024.","FDA Breakthrough Therapy Designation granted for atacicept in IgAN during 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178957,"accession_number":"0001193125-25-005010","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vera Therapeutics releases corporate presentation at J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation furnished as Exhibit 99.1, available on company website.","No specific financial results, guidance, or material events disclosed in the filing.","Presentation contains forward-looking statements as noted in slides."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195645,"accession_number":"0000950170-24-122814","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics reports Q3 net loss $46.6M, raises $345M; atacicept Ph3 enrollment done","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $46.6M ($0.85/shr) vs $20.1M ($0.45) in Q3 2023; cash $353.3M as of Sept 30.","Completed $345M public equity offering to fund atacicept launch and regulatory submission.","Phase 3 ORIGIN 3 trial enrollment complete; topline data expected in Q2 2025.","Positive 96-week eGFR stabilization data from Phase 2 ORIGIN trial at ASN Kidney Week 2024.","Expanded atacicept development with PIONEER trial in broader IgAN and other kidney diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195644,"accession_number":"0001193125-24-248079","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vera Therapeutics launches $300M public offering of 7.1M shares at $42.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["7,142,858 shares offered at $42.00/share; gross proceeds ~$300M before discounts and expenses.","Underwriters have 30-day option to purchase up to 1,071,428 additional shares at the same price.","Closing expected October 31, 2024; J.P. Morgan, Goldman Sachs, Evercore, Cantor Fitzgerald are underwriters.","Offering made under automatic shelf registration statement on Form S-3; customary closing conditions apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195643,"accession_number":"0001193125-24-245704","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Vera Therapeutics reports positive 96-week ORIGIN Phase 2b data for atacicept in IgAN; cash ~$353M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Atacicept showed -66% Gd-IgA1 reduction, 75% hematuria resolution, -52% proteinuria reduction over 96 weeks.","Mean annualized eGFR slope of -0.6 mL/min/1.73m2/year; 90% treatment completion rate.","Phase 3 ORIGIN 3 topline expected Q2 2025; BLA submission planned H2 2025; commercial launch target 2026.","Preliminary unaudited cash, cash equivalents and marketable securities ~$353.2M as of Sep 30, 2024.","Data simultaneously published in Journal of the American Society of Nephrology; presented at ASN Kidney Week."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195642,"accession_number":"0001193125-24-230760","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vera expands atacicept program to broader IgAN and autoimmune kidney diseases with two new studies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORIGIN Extend to start Q4 2024, providing extended atacicept access and long-term data for ORIGIN participants.","PIONEER study in 2025 will evaluate atacicept in expanded IgAN populations (low eGFR, high/low proteinuria, recurrence post-transplant, adolescents) and podocytopathies (pMN, FSGS, MCD).","Combined US peak prevalence of IgAN and autoimmune-driven pMN, FSGS, MCD estimated at ~230,000.","96-week Phase 2b ORIGIN data to be presented as Late Breaking Oral at ASN Kidney Week 2024.","Multiple regulatory and clinical milestones expected over next 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211904,"accession_number":"0000950170-24-093342","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q2 net loss $33.7M; gets FDA Breakthrough Therapy Designation for atacicept in IgAN","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.7M ($0.62/diluted share) vs $20.2M ($0.46) in Q2 2023; cash $384.4M sufficient through approval and US launch.","FDA granted Breakthrough Therapy Designation for atacicept in IgA Nephropathy (IgAN).","Phase 2b ORIGIN data: atacicept stabilized kidney function through 72 weeks, reduced hematuria; 96-week data expected Q4 2024.","Phase 3 ORIGIN 3 enrollment on track to complete Q3 2024; topline data expected Q2 2025.","Appointed David L. Johnson COO, Amit Sharma EVP Medical Affairs; Christy J. Oliger to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211903,"accession_number":"0001193125-24-174318","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Appoints David Johnson as COO effective July 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Johnson named COO; previously Chief Commercial Officer at Global Blood Therapeutics.","Annual base salary of $500,000; eligible for bonus up to 40% of base salary.","Granted option to purchase 160,000 shares at $36.29, vesting over 4 years.","Severance: 9 months salary without change in control; 12 months with change in control.","Johnson also receives up to $10,000 reimbursement for legal fees related to offer letter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230696,"accession_number":"0001193125-24-159935","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vera Therapeutics appoints Christy Oliger to board; grants 25K share options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christy Oliger appointed as Class III Director effective June 7, 2024, term through 2027 annual meeting.","Received nonstatutory stock option for 25,000 shares vesting monthly over three years.","Annual cash retainer of $40,000 for board service plus $4,000 for Nominating Committee, prorated for 2024.","Awarded 2,987 restricted stock units, fully vested for prior consulting services, settling in 2025.","Will serve on Nominating and Corporate Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230695,"accession_number":"0000950170-24-061872","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vera Therapeutics stockholders re-elect two Class III directors; ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Andrew Cheng re-elected with 27.4M votes for, 13.0M withheld; Scott Morrison with 31.6M for, 8.8M withheld.","Broker non-votes were 1,020,833 for both director elections.","KPMG ratified as independent auditor for FY2024: 41.4M for, 1,832 against, 7,116 abstain.","Meeting held May 15, 2024; 54,451,375 Class A shares outstanding as of record date March 18."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230694,"accession_number":"0000950170-24-056283","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q1 net loss $28.4M; cash $403.7M; Phase 3 enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $28.4M ($0.56 diluted EPS) vs $30.1M ($0.80) in Q1 2023.","Cash and equivalents $403.7M after $287.5M financing; runway through approval and launch.","Positive 72-week Phase 2b ORIGIN data; 96-week topline results expected Q4 2024.","Pivotal Phase 3 ORIGIN 3 enrollment estimated complete Q3 2024; data 1H 2025.","Appointed Robert M. Brenner as CMO and William D. Turner as CDO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249079,"accession_number":"0000950170-24-033947","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics FY23 net loss $96.0M; raises $287.5M; Phase 3 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2023 net loss $96.0M ($2.25 diluted EPS) vs $89.1M ($3.35) prior year; no revenue.","Cash $160.7M at Dec 31, 2023; subsequent $287.5M gross from Feb 2024 offering.","Phase 2b 72-week data: sustained reductions in Gd-IgA1, hematuria, UPCR with stable eGFR; Phase 3 topline 1H 2025.","Appointed Robert M. Brenner, M.D. as CMO and William D. Turner as CDO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249078,"accession_number":"0001193125-24-019496","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vera Therapeutics announces $250M public offering of 8.1M shares at $31.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 8,064,517 shares of Class A common stock at $31.00/share; gross proceeds ~$250.0M.","Underwriters granted 30-day option to purchase up to 1,209,677 additional shares at same price less discounts.","Underwriters include J.P. Morgan, Cowen, and Evercore as representatives; closing expected Feb 1, 2024.","Use of proceeds not specified in the filing; likely general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249077,"accession_number":"0001193125-24-017311","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Vera Therapeutics reports preliminary cash of $160.7M; suspends ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities as of Dec 31, 2023: approximately $160.7 million.","Company suspended and terminated the ATM prospectus effective Jan 29, 2024; no further sales under current Sales Agreement until new prospectus filed.","Estimate is unaudited and subject to change upon completion of quarter-end and year-end financial close for Q4 and FY2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249076,"accession_number":"0001193125-24-014808","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vera Therapeutics reports positive 72-week Phase 2b atacicept data with eGFR stabilization in IgAN","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Atacicept 150mg for 72 weeks: 62% reduction in Gd-IgA1, hematuria to 19%, 48% reduction in UPCR (PP analysis).","eGFR stable with 0 mL/min/1.73m² change from baseline; placebo-to-atacicept switchers halted eGFR decline (-3.2 vs -4.9 at 36wks).","Safety consistent with prior trials; generally well-tolerated in OLE.","Phase 3 ORIGIN 3 enrollment on track for H2 2024; topline data expected H1 2025; BLA submission planned H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249075,"accession_number":"0001193125-24-003931","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vera Therapeutics appoints new CMO and CDO; prior CMO departed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Celia Lin separated as CMO effective Jan 3, 2024; received target 2023 bonus and severance.","Dr. Robert Brenner appointed CMO effective Jan 3, 2024; brings 25+ yrs nephrology and biotech experience.","William D. Turner appointed CDO effective immediately; led drug development, NDA/MAA filings at Sierra and Aimmune.","Both execs to support atacicept Phase 3 trial in IgA nephropathy and pipeline development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249074,"accession_number":"0001193125-24-003928","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vera Therapeutics posts updated corporate presentation on January 8, 2024","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Exhibit 99.1 furnished under Item 7.01; no specific financial or operational details disclosed in the filing.","Presentation available on company website; content not summarized in this filing.","Forward-looking statements disclaimer included in the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266603,"accession_number":"0001193125-23-303004","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2023-12-26T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"Vera Therapeutics draws $25M in new term loans from Oxford Finance","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Total borrowings under the Loan Agreement now $50M, after draws of $5M (Dec 2021), $20M (Nov 2022), and this $25M.","Loan bears floating interest at the greater of 8.25% or 1-Month CME Term SOFR + 8.25% per annum.","Final maturity date is December 17, 2027; a final fee of 7% of aggregate principal is due at maturity or prepayment.","Prepayment fee: 3% if within first year after funding, 2% if within second year, none thereafter.","Proceeds use not specified; lender is Oxford Finance LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266602,"accession_number":"0000950170-23-061548","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q3 net loss $20.1M ($0.45/diluted); cash $159.9M; hematuria resolution data at ASN","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.1M ($0.45 per diluted share) vs $24.7M ($0.91) in Q3 2022.","Cash, cash equivalents and securities $159.9M; cash burn $67.0M in nine months.","Phase 2b OLE eGFR and proteinuria data expected Q1 2024; pivotal Phase 3 ORIGIN 3 enrolling.","At ASN Kidney Week: 80% of atacicept patients achieved hematuria resolution vs 5% placebo.","Enrollment of Phase 3 ORIGIN 3 estimated to complete H2 2024; topline data H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283841,"accession_number":"0000950170-23-040973","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q2 net loss $20.2M, cash $181M; Phase 3 atacicept trial initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.2M ($0.46 per share) vs $14.9M ($0.55 per share) in Q2 2022.","Cash, cash equivalents, and marketable securities of $181.0M as of June 30, 2023; funds operations to early 2026.","Positive 36-week Phase 2b ORIGIN results: significant proteinuria reduction and eGFR stabilization.","Pivotal Phase 3 ORIGIN 3 trial for IgA nephropathy initiated in June 2023.","Preliminary ORIGIN 3 data expected in first half of 2025; additional Phase 2b data in H2 2023 and 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303426,"accession_number":"0001193125-23-169612","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vera's atacicept shows 43% placebo-adjusted proteinuria reduction at week 36 in Phase 2b IgAN trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Atacicept 150 mg achieved 43% placebo-adjusted UPCR reduction (PP, p=0.003) and 35% (ITT, p=0.012).","Patients on atacicept had stable eGFR vs. placebo decline; delta 11% (p=0.038), 5.8 mL/min/1.73 m² difference.","Gd-IgA1 reduced 64% from baseline (p<0.0001); safety consistent with prior studies, low SAE rate (3% vs 9% placebo).","Phase 3 ORIGIN 3 trial initiated June 2023; topline results expected H1 2025, BLA submission H2 2025.","Company targets commercial launch in 2026 if atacicept receives FDA approval for IgAN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303425,"accession_number":"0001193125-23-146313","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vera Therapeutics annual meeting elects three Class II directors, ratifies KPMG","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Maha Katabi, Ph.D., Michael M. Morrissey, Ph.D., and Patrick G. Enright as Class II directors to serve until 2026.","Katabi received 27,427,581 votes for, 1,803,342 withheld; Morrissey 25,666,331 for, 3,564,592 withheld; Enright 29,205,775 for, 25,148 withheld.","Stockholders ratified KPMG LLP as independent auditor for FY2023 with 35,575,486 votes for, 3,251 against, 12,777 abstentions.","44,261,109 shares of Class A common stock were outstanding and entitled to vote as of March 17, 2023 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303424,"accession_number":"0000950170-23-020841","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics reports Q1 net loss of $30.1M; atacicept Phase 3 to start Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.1M ($0.80 per diluted share) vs $17.1M ($0.71) in Q1 2022.","Cash, cash equivalents, and marketable securities of $197.2M as of March 31, 2023; expected to fund operations to early 2026.","36-week data from Phase 2b ORIGIN trial of atacicept in IgAN selected as late-breaking presentation at ERA Congress 2023.","Plan to initiate pivotal Phase 3 trial of atacicept in IgAN in Q2 2023.","Appointed Kerry Cooper, M.D., as Senior Vice President of Medical Affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323058,"accession_number":"0000950170-23-010114","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics reports FY2022 net loss $89.1M; positive atacicept interim data; plans Phase 3 in Q2 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Positive interim Phase 2b ORIGIN data: 41% mean proteinuria reduction vs baseline at 24 weeks in 150mg dose.","36-week data on track for Q2 2023; Phase 3 initiation planned for Q2 2023.","FY2022 net loss $89.1M ($3.35/share) vs $32.6M ($2.43) prior year.","Cash $114.7M as of Dec 31, 2022; raised ~$107.6M net in Feb 2023 offering.","Prioritizing atacicept for IgAN; funds expected to last to early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323057,"accession_number":"0001193125-23-067568","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vera Therapeutics discloses minimal exposure to Silicon Valley Bank failure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company holds approximately 1.2% of its cash and investments at SVB.","SVB closed and FDIC appointed as receiver; Vera considers risk minimal.","Vera expects no material impact on operations or liquidity from this exposure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323056,"accession_number":"0001193125-23-022827","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vera Therapeutics announces $100M follow-on public offering of 14.3M shares at $7.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriting agreement signed for 14,285,715 shares of Class A common stock at $7.00 per share.","Gross proceeds of approximately $100 million before underwriting discounts and offering expenses.","Closing expected February 6, 2023; underwriters have 30-day option for 2,142,857 additional shares.","Lead underwriters: J.P. Morgan, Cowen, and Evercore."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323055,"accession_number":"0001193125-23-021527","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2023-02-01T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Vera Therapeutics reports preliminary cash of $114.7M as of Dec 31, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities total approximately $114.7 million at Dec 31, 2022.","Quarter-end financial close for Q4 2022 is not yet complete; figure is subject to change upon finalization.","No additional financial results, revenue, or earnings data were provided in this filing.","The cash balance excludes any subsequent financing or operating activities through the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323054,"accession_number":"0001193125-23-018203","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2023-01-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vera Therapeutics announces positive per-protocol analysis from Phase 2b ORIGIN trial of atacicept in IgA nephropathy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At Week 24, atacicept 150 mg achieved 41% mean reduction in proteinuria and 34% delta vs placebo (p=0.025).","At Week 36 interim, atacicept 150 mg showed 47% mean reduction from baseline and 48% delta vs placebo.","Serious treatment-emergent AEs occurred in 2% of atacicept patients vs 9% in placebo; discontinuation rate 1%.","Company plans to advance atacicept into pivotal Phase 3 in first half of 2023, after FDA discussions.","Prespecified per-protocol analysis excluded 14 patients with protocol violations identified by blinded CRO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323053,"accession_number":"0001193125-23-000830","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vera Therapeutics reports positive Phase 2b ORIGIN topline: primary endpoint met in IgA nephropathy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["UPCR reduced 31% with pooled 75/150 mg dose (p=0.037 vs placebo) and 33% with 150 mg (p=0.047) at week 24.","eGFR stabilized in atacicept arm through week 24; Gd-IgA1 reduced robustly from baseline.","Safety well-tolerated: 1% discontinuation due to AEs, serious TEAEs 2% atacicept vs 9% placebo.","Company plans to advance atacicept into pivotal Phase 3 development in H1 2023 subject to FDA discussions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341125,"accession_number":"0000950170-22-023518","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q3 net loss $24.7M; cash $114.4M; atacicept Ph2b ORIGIN data early Q1 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.7M ($0.91 per share) vs $7.6M loss YoY; cash burn $46.4M YTD.","Cash, equivalents, and marketable securities $114.4M; additional $20M drawn from credit facility in Nov 2022; funds operations to Q2 2024.","Phase 2b ORIGIN trial of atacicept in IgA nephropathy topline data expected early Q1 2023.","Initiated pivotal Phase 3 COMPASS trial of atacicept in lupus nephritis.","Positive Phase 2 MAU868 results in BK viremia presented; plan to start Ph2b/Ph3 trial in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358233,"accession_number":"0001193125-22-241970","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2022-09-09T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Vera Therapeutics restructures Novartis license milestone payments, issues ~$7M in stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended license with Novartis for MAU868; capped total milestone payments at $62.0M.","Issuing 283,034 shares of Class A common stock to Novartis, valued at ~$7M based on closing price plus 20% premium.","Share issuance expected to close on or about September 13, 2022.","Modification adjusts development and regulatory milestone payment structure under the existing license."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358232,"accession_number":"0000950170-22-016259","cik":1831828,"company_name":"Vera Therapeutics, Inc.","ticker":"VERA","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vera Therapeutics Q2 net loss $14.9M, cash $131.9M; Phase 2b atacicept enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.9M ($0.55 per share) vs $3.4M ($0.33) in Q2 2021.","Cash, equivalents, and securities $131.9M at June 30, 2022; plus $45M credit facility.","Completed enrollment in Phase 2b ORIGIN trial of atacicept for IgA nephropathy; topline data expected early Q1 2023.","Appointed Michael M. Morrissey, Ph.D., CEO of Exelixis, as Chairman of the board.","Plan to initiate Phase 3 atacicept trial in lupus nephritis in H2 2022 and Phase 2b/3 MAU868 in BKV in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2386780000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-10T23:59:59+00:00|358232"}